Ocean Biomedical Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company develops an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and … Read more
Ocean Biomedical Inc. (OCEA) - Total Liabilities
Latest total liabilities as of March 2025: $98.52 Million USD
Based on the latest financial reports, Ocean Biomedical Inc. (OCEA) has total liabilities worth $98.52 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ocean Biomedical Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Ocean Biomedical Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ocean Biomedical Inc. Competitors by Total Liabilities
The table below lists competitors of Ocean Biomedical Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CHECK PNT SFTWARE - Dusseldorf Stock Exchang
DU:CPW
|
Germany | €2.68 Billion |
|
Omniq Corp
OTCQB:OMQS
|
USA | $38.10 Million |
|
ORACLE - Dusseldorf Stock Exchang
DU:ORC
|
Germany | €132.94 Billion |
|
PTC (PMTA.SG)
STU:PMTA
|
Germany | €3.17 Billion |
|
Medallion Resources Ltd
PINK:MLLOF
|
USA | $1.45 Million |
|
TTGXF
OTCQB:TTGXF
|
USA | $221.61K |
Liability Composition Analysis (2019–2024)
This chart breaks down Ocean Biomedical Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 109.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ocean Biomedical Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ocean Biomedical Inc. (2019–2024)
The table below shows the annual total liabilities of Ocean Biomedical Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $98.52 Million | +2.34% |
| 2023-12-31 | $96.26 Million | +1355.49% |
| 2022-12-31 | $6.61 Million | -1.89% |
| 2021-12-31 | $6.74 Million | +196.83% |
| 2020-12-31 | $2.27 Million | +878.88% |
| 2019-12-31 | $232.00K | -- |